CAPRICOR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CAPRICOR THERAPEUTICS, INC. (CAPR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $27.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $27.43, a 159.02% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $21.61, a 69.76% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $5.50, a 32.21% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $10.59, a 153.35% increase year-over-year.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $12.24, a 107.81% increase from fiscal 2024.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.89, a 52.99% increase from fiscal 2023.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.85, a 26.64% increase from fiscal 2022.
- CAPRICOR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.04, a 11.88% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.43 10-Q · filed 2026-08-14 | $22.19 10-Q · filed 2026-08-14 | ||||||
| 2026-03-31 | $21.61 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $12.24 10-K · filed 2026-03-17 | |||||||
| 2025-09-30 | $5.50 10-Q · filed 2025-11-10 | $12.01 10-Q · filed 2025-11-10 | ||||||
| 2025-06-30 | $10.59 10-Q · filed 2026-08-14 | $12.33 10-Q · filed 2026-08-14 | ||||||
| 2025-03-31 | $12.73 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | $5.89 10-K · filed 2026-03-17 | |||||||
| 2024-09-30 | $4.16 10-Q · filed 2025-11-10 | $4.56 10-Q · filed 2025-11-10 | ||||||
| 2024-06-30 | $4.18 10-Q · filed 2025-08-11 | $4.57 10-Q · filed 2025-08-11 | ||||||
| 2024-03-31 | $4.59 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | $3.85 10-K · filed 2025-03-26 | |||||||
| 2023-09-30 | $4.93 10-Q · filed 2024-11-14 | $3.88 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | $4.16 10-Q · filed 2024-08-08 | $3.55 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | $3.47 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | $3.04 10-K · filed 2024-03-11 | |||||||
| 2022-09-30 | $4.41 10-Q · filed 2023-11-14 | $3.04 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $3.04 10-Q · filed 2023-08-08 | $2.90 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $2.87 10-Q · filed 2023-05-12 | |||||||
| 2021-12-31 | $3.45 10-K · filed 2023-03-17 | |||||||
| 2021-09-30 | $4.03 10-Q · filed 2022-11-10 | $3.40 10-Q · filed 2022-11-10 | ||||||
| 2021-06-30 | $3.82 10-Q · filed 2022-08-12 | $3.27 10-Q · filed 2022-08-12 | ||||||
| 2021-03-31 | $3.26 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | $3.93 10-K · filed 2022-03-11 | |||||||
| 2020-09-30 | $5.23 10-Q · filed 2021-11-12 | $3.91 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | $3.92 10-Q · filed 2021-08-13 | $3.75 10-Q · filed 2021-08-13 | ||||||
| 2020-03-31 | $1.03 10-Q · filed 2021-05-14 | |||||||
| 2019-12-31 | $2.73 10-K · filed 2021-03-15 | |||||||
| 2019-09-30 | $2.73 10-Q · filed 2020-11-13 | $2.73 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-14 | |||||||
| 2018-12-31 | $13.09 10-K · filed 2020-03-27 | $1.31 10-K · filed 2019-03-29 | ||||||
| 2018-09-30 | $10.53 10-Q · filed 2019-11-08 | $1.05 10-Q · filed 2018-11-14 | $13.09 10-Q · filed 2019-11-08 | $1.31 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $13.02 10-Q · filed 2019-08-08 | $1.30 10-Q · filed 2018-08-13 | $14.33 10-Q · filed 2019-08-08 | $1.43 10-Q · filed 2018-08-13 | ||||
| 2018-03-31 | $1.45 10-Q · filed 2019-05-14 | |||||||
| 2017-12-31 | $1.83 10-K · filed 2019-03-29 | |||||||
| 2017-09-30 | $1.91 10-Q · filed 2018-11-14 | |||||||
| 2017-06-30 | $2.81 10-Q · filed 2018-08-13 | $1.78 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $1.86 10-Q · filed 2018-05-14 | |||||||
| 2016-12-31 | $2.09 10-K · filed 2018-03-22 | |||||||
| 2016-09-30 | $2.42 10-Q · filed 2017-11-14 | $2.02 10-Q · filed 2017-11-14 | ||||||
| 2016-06-30 | $2.15 10-Q · filed 2017-08-14 | $2.00 10-Q · filed 2017-08-14 | ||||||
| 2016-03-31 | $1.59 10-Q · filed 2017-05-15 | |||||||
| 2015-12-31 | $3.84 10-K · filed 2017-03-16 | |||||||
| 2015-09-30 | $3.11 10-Q · filed 2016-11-14 | $3.86 10-Q · filed 2016-11-14 | ||||||
| 2015-06-30 | $3.53 10-Q · filed 2016-08-15 | $4.15 10-Q · filed 2016-08-15 | ||||||
| 2015-03-31 | $4.23 10-Q · filed 2016-05-13 | |||||||
| 2014-12-31 | $4.40 10-K · filed 2016-03-30 | |||||||
| 2014-09-30 | $3.83 10-Q · filed 2015-11-13 | $4.40 10-Q · filed 2015-11-13 | ||||||
| 2014-06-30 | $4.05 10-Q · filed 2015-08-14 | $4.92 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | $10.65 10-Q · filed 2015-05-13 | |||||||
| 2013-12-31 | $0.53 10-K · filed 2015-03-16 | |||||||
| 2013-09-30 | $0.26 10-Q · filed 2014-11-14 | |||||||
| 2013-06-30 | $0.26 10-Q · filed 2014-08-14 | |||||||
| 2013-03-31 | $0.25 10-Q · filed 2014-05-15 | |||||||
| 2012-12-31 | $0.60 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |